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Lupus Anticoagulant (LA) is by far the most enigmatic antibody population in patients with antiphospholipid syndrome, that was an unsolved paradox only 50 years 
ago. In 1952, Conley and Hartman described patients with bleeding symptoms, whose plasma lengthened the blood clotting time and they failed to correct the addition of 
normal plasma. Other patients have been reported, and in 1972 the term "lupus anticoagulant" was coined, as the apparent coagulation inhibitor was observed in patients 
with systemic lupus erythematosus (SLE). However, the notion of "lupus anticoagulant" has proven to be wrong, as LA is often found in plasma in patients with clinical 
conditions other than SLE and it is associated with thromboembolic events, which may occur in healthy individuals.
Introduction:
Purpose: The goal of the research is to present the
reasons that cause the respective prolongation
of the coagulation time induced by LA to be
mostly associated with thrombosis, than with a
tendency to bleed.
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Material and methods:
For the research was studied the specialty
literature on biochemical perspectives and
mechanisms of The lupus anticoagulant paradox.
Results:
Conclusions:
Lupus anticoagulants are a heterogeneous class of immunoglobulins (predominantly IgG
autoantibodies and, rarely, IgM), which bind specifically to the epitopes of negatively charged plasma
phospholipid binding proteins, prothrombin, beta2-glycoprotein I (most commonly, domain D I of the
molecule is involved) or annexin V, inhibiting phospholipid-dependent coagulation in vitro. LA forms an
APLA subgroup that disrupts the in vitro assembly of the prothrombinase complex (factors Xa, Va and
prothrombin in the complex on phospholipid membranes), leading to prolongation of aPTT, diluted
Russell viper venom time (dRVVT), coagulation time kaolin plasma and rarely prothrombin time. In vivo,
the mechanism of thrombosis is explained by Ig G binding to phospholipids, a phenomenon that is
essential for the degradation of the normal effects of protein C and protein S, thus changing the balance
in favor of thrombus formation. There are many mechanisms for inducing LA, including infections,
oxidative stress, and major stress, such as surgery or trauma. All of these stressors help expose
phospholipids, which eventually allow antibodies to attach. At this turn, this leads to intravascular
coagulation and thrombus formation.
Lupus anticoagulant has procoagulant properties in vivo and prolongs coagulation times addicted to
phospholipid in vitro. Extended in vitro coagulation time may be mistaken as a bleeding disorder.
Different thromboplastin reagents and plasma mixing assays, as well as independent thromboplastin
coagulation assays may be useful to differentiate in vitro changes associated with LA from in vivo
coagulation factor deficiency.
Laboratory Diagnosis of the Lupus Anticoagulant
β2GPI and antibody. β2GPI and antibody to β2GPI binding to a
phospholipid surface. B2GPI consists of 5 homologous domains.
Domain V binds to the anionic phospholipid surface. The anti-
β2GPI antibody binds to domain I.
The prevalence of thrombosis in patients with
lupus anticoagulants is 24-36%; deep limb thrombosis
and pulmonary embolism predominate. Patients with
recurrent miscarriages have lupus anticoagulants in
approximately 10% of cases. The prevalence of LA in
patients with SLE is attested only in 5-10% of cases.
